Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

176.83USD
11 Dec 2017
Change (% chg)

$1.42 (+0.81%)
Prev Close
$175.41
Open
$176.09
Day's High
$177.69
Day's Low
$175.01
Volume
1,873,520
Avg. Vol
2,592,313
52-wk High
$191.10
52-wk Low
$142.79

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $127,332.00
Shares Outstanding(Mil.): 725.91
Dividend: 1.15
Yield (%): 2.62

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

Amgen's Kyprolis improves overall survival in blood cancer patients

Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

5:36pm EST

UPDATE 1-Amgen's Kyprolis improves overall survival in blood cancer patients

Dec 11 Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

5:35pm EST

Amgen's Kyprolis improves overall survival in blood cancer patients

Dec 11 Amgen Inc said on Monday new data from a late-stage trial testing Kyprolis in combination with two other drugs showed improved overall survival rate in patients with blood cancer.

4:26pm EST

BRIEF-Kyprolis (Carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma

* KYPROLIS® (CARFILZOMIB) EXTENDED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN PHASE 3 ASPIRE TRIAL

4:09pm EST

BRIEF-Carmot Enters A Multi-Year Drug Discovery Collaboration With Amgen

* CARMOT ENTERS A MULTI-YEAR DRUG DISCOVERY COLLABORATION WITH AMGEN

Dec 06 2017

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

Dec 05 2017

BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests

* BIOCARTIS AND AMGEN SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS

Dec 04 2017

FDA approves heart protection claims for Amgen cholesterol drug

Amgen Inc can now promote the ability of its potent but expensive cholesterol drug to reduce the risk of heart attacks and strokes, after U.S. health regulators approved adding those benefits to the medicine's prescribing label, the company said on Friday.

Dec 01 2017

FDA approves heart protection claims for Amgen cholesterol drug

Dec 1 Amgen Inc can now promote the ability of its potent but expensive cholesterol drug to reduce the risk of heart attacks and strokes, after U.S. health regulators approved adding those benefits to the medicine's prescribing label, the company said on Friday.

Dec 01 2017

BRIEF-Amgen Says Aimovig Phase 3 Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention

* AIMOVIG™ (ERENUMAB) PHASE 3 STRIVE DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE DEMONSTRATE SIGNIFICANT, SUSTAINED EFFICACY IN MIGRAINE PREVENTION Source text for Eikon: Further company coverage:

Nov 29 2017

Earnings vs. Estimates